James Posada, Ph.D.
Founder and Chief Executive Officer
Jim Posada founded Resolve in 2010 and has served as its chief executive officer since inception. Prior to founding Resolve, Jim was the chief business officer of GlycoFi, designing the business strategy and executing company transforming partnering deals, including the 2006 sale of the company to Merck. Jim is a scientist by training and has made important contributions to the field of signal transduction through the identification of and cloning of first full length MAP kinase ERK2 and identifying the upstream activating kinase MEK while a postdoctoral fellow at the Fred Hutchinson Cancer Center. Following his postdoctoral training with Jonathan Cooper he was a faculty member at the University of Vermont School of Medicine where he built an NIH-funded basic research group. From academics, Jim pivoted into drug discovery joining Eli Lilly and company where he led multiple drug discovery teams as a member of the biotherapeutics management team.
Member of the Board of Managers and Lead Investor
Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, Alexar Therapeutics, Ario Pharmaceuticals, Cambridge Epigenetix, Dali Wireless, Oxyrane UK, Resolve Therapeutics, Svelte Medical Systems, Vascular Therapies, Vaultive, and iCAD. Somu has also served on the Boards of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco) and K2M (acquired by Welsh Carson). Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.
Peter Kiener, D. Phil
Chairman of the Board of Managers
Dr. Peter A Kiener currently is Chairman of the Board of Managers of Resolve. He is currently the Chief Scientific Officer and Head of R&D at Sucampo LLC Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener previously worked on biologics for Bristol-Myers Squibb from 1983 to 2001. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener serves as a member of the Board of Directors of Tetragenics, and Imagen Pharma LLC. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.
Daniel Burge, MD
Dan has been providing clinical and strategic consulting services to the biopharma and pharmaceutical industry since founding Burge Consulting in 2008. Prior to that Dan was the chief medical officer of Trubion Pharmacueitcals, where he managed the development of two novel oncology biotherapeutic molecules. Dan began his industry career at Immunex Corporation where he was the inflammation area head and was instrumental in the development of the first anti-TNF therapy, Enbrel. Dan is a rhematologist by training and was in private practice prior to joining Immunex.
Raj Dua, Ph.D.
Dr. Dua is managing the CMC and manufacturing functions within Resolve Therapeutics in the areas of process development, manufacturing, and drug supply. Dr. Dua has over 20 years of experience in product development and bringing biologics and pharmaceutical candidates from research laboratory into clinical development and commercialization. Dr. Dua was most recently Vice President, Pharmaceutical Operations at Alder Bio-Pharmaceuticals where he oversaw all the process development, manufacturing and supply chain management functions for their monoclonal antibody based products. Prior to that, he was Senior Director of Product Development at Trubion Pharmaceuticals and Director of Process and Assay Development at Xcyte Therapies. Dr. Dua’s career has encompassed the development of cell based therapies, monoclonal antibodies, and fusion proteins. Dr. Dua received his PhD at the University of Georgia and his MBA at the University of Washington. He has published several scientific articles and is the inventor on numerous patents.
Betty Diamond, MD
The Feinstein Institute
Michelle Petri, MD
Vibeke Strand, MD
Victoria Werth, MD
University of Pennsylvania
David Wofsy, MD
University of California San Francisco